1. Randomized phase II study of tegafur–uracil/leucovorin versus tegafur–uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial).
- Author
-
Kosugi, Chihiro, Koda, Keiji, Takiguchi, Nobuhiro, Takaishi, Satoru, Miyauchi, Hideaki, Hirayama, Nobuo, Nomura, Yukihiro, Kondo, Eisuke, Kawasaki, Yohei, Ozawa, Yoshihito, and Matsubara, Hisahiro
- Subjects
- *
COLORECTAL cancer , *SURVIVAL rate , *OXALIPLATIN , *PROGRESSION-free survival , *ALANINE aminotransferase - Abstract
Purpose: This randomized phase II trial compared tegafur–uracil/leucovorin (UFT/LV) plus oxaliplatin (TEGAFOX) to UFT/LV as adjuvant chemotherapy for patients with high-risk stage II/III colorectal cancer. Methods: From 2010 to April 2015, 159 patients who underwent curative resection were randomly assigned to receive TEGAFOX (85 mg/m2 oxaliplatin on days 1 and 15, 300 mg/m2/day UFT and 75 mg/day LV on days 1–28, every 35 days for five cycles) or UFT/LV. The primary study endpoint was disease-free survival. Results: The 3-year disease-free survival rate was 84.2% in the TEGAFOX arm, versus 62.1% for UFT/LV. The stratified hazard ratio for disease-free survival for TEGAFOX compared to UFT/LV was 0.338 (P < 0.01). The incidence of any-grade adverse events was significantly higher in the TEGAFOX arm (96.1%) than in the UFT/LV arm (76.6%; P < 0.01). The rates of any-grade neutropenia, thrombocytopenia, aspartate aminotransferase/alanine aminotransferase elevation, and peripheral sensory neuropathy were higher in the TEGAFOX group, whereas the incidence of grade ≥ 3 adverse events did not differ between the groups. Conclusions: TEGAFOX is an additional adjuvant chemotherapy option for high-risk stage II/III colorectal cancer. Trial registration: UMIN ID: 000007696, date of registration: April 10, 2012 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF